首页> 外文期刊>Molecular cancer research: MCR >De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer
【24h】

De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer

机译:De Novo脂肪酸合成驱动的鞘脂代谢促进结直肠癌的转移性潜力

获取原文
获取原文并翻译 | 示例
           

摘要

Metastasis is the most common cause of death in colorectal cancer patients. Fatty acid synthase (FASN) and sphingosine kinase-1 and -2 (SPHK1 and 2) are overexpressed in many cancers, including colorectal cancer. However, the contribution of FASN-mediated upregulation of sphingolipid metabolism to colorectal cancer metastasis and the potential of these pathways as targets for therapeutic intervention remain unknown. This study determined that sphingosine kinases (SPHK) are overexpressed in colorectal cancer as compared with normal mucosa. FASN expression significantly correlated with SPHK2 expression in data sets from The Cancer Genome Atlas (TCGA) and a colorectal cancer tumor microarray. FASN, SPHK1, and SPHK2 colocalized within invadopodia of primary colorectal cancer cells. Moreover, FASN inhibition decreased SPHK2 expression and the levels of dihydrosphingosine 1-phosphate (DH-S1P) and sphingosine 1-phosphate (S1P) in colorectal cancer cells and tumor tissues. Inhibition of FASN using TVB-3664 and sphingolipid metabolism using FTY-720 significantly inhibited the ability of primary colorectal cancer cells to proliferate, migrate, form focal adhesions, and degrade gelatin. Inhibition of the FASN/SPHK/S1P axis was accompanied by decreased activation of p-MET, p-FAK, and p-PAX. S1P treatment rescued FASN-mediated inhibition of these proteins, suggesting that FASN promotes metastatic properties of colorectal cancer cells, in part, through an increased sphingolipid metabolism. These data demonstrate that upregulation of the FASN/SPHK/S1P axis promotes colorectal cancer progression by enhancing proliferation, adhesion, and migration.
机译:转移是结肠直肠癌患者中最常见的死因。脂肪酸合酶(FASN)和鞘氨醇激酶-1和-2(SPHK1和2)在许多癌症中过表达,包括结肠直肠癌。然而,Fasn介导的鞘脂代谢对直肠癌转移的贡献和这些途径作为治疗干预靶的潜力仍然未知。该研究确定,与正常粘膜相比,鞘氨酸激酶(SPHK)在结肠直肠癌中过表达。 FasN表达与来自癌症基因组Atlas(TCGA)和结直肠癌肿瘤微阵列的数据集中的SPHK2表达显着相关。 FasN,SPHK1和SPHK2在原发性结肠直肠癌细胞的invidopodia内粘连。此外,FasN抑制在结肠直肠癌细胞和肿瘤组织中降低了SPHK2表达和二氢磷素1-磷酸二磷酸酯(DH-S1P)和鞘氨醇1-磷酸(S1P)的水平。使用TVB-3664抑制FASN和使用FTY-720的鞘脂代谢显着抑制原发性结肠直肠癌细胞增殖,迁移,形成局灶性粘连的能力,降解明胶。 FasN / SPHK / S1P轴的抑制伴随着P-Met,P-Fak和P-Pax的活化。 S1P处理救出了Fasn介导的这些蛋白质的抑制,表明FasN通过增加的鞘脂代谢部分促进结肠直肠癌细胞的转移性。这些数据表明,FasN / SPHK / S1P轴的上调通过增强增殖,粘附和迁移来促进结肠直肠癌进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号